Skip to main content

Table 3 Analysis of covariance with mean differences of outcome measures (DAS28, HAQ) between nulliparous and parous women with incident RA included in the EIRA study, at baseline and follow-up visits during the first 24 months

From: Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material

Outcome measure above median ACPA-negative RA
18–44 years 45–70 years
  Beta (95 % CI), p-value Beta (95 % CI), p-value
DAS28   
 Baseline 0.02 (−0.58 to 0.62), p = 0.95 −0.78 (−1.19 to −0.37), p < 0.001
 3 months 1.60 (0.81 to 2.40), p < 0.001 −0.45 (−0.96 to 0.06), p = 0.96
 6 months 1.30 (0.48 to 2.12), p = 0.002 −0.27 (−0.82 to 0.28), p = 0.34
 12 months 1.22 (0.59 to 1.85), P < 0.001 −0.31 (−0.73 to 0.12), p = 0.16
 24 months 0.86 (0.18 to 1.55), p = 0.014 −0.29 (−0.76 to 0.19), p = 0.24
HAQ   
 Baseline 0.06 (−0.23 to 0.34), p = 0.68 −0.35 (−0.56 to −0.14), p = 0.001
 3 months 0.40 (0.05 to 0.74), p = 0.026 −0.12 (−0.32 to 0.08), p = 0.24
 6 months 0.44 (0.13 to 0.75), p = 0.006 −0.09 (−0.30 to 0.12), p = 0.38
 12 months 0.43 (0.16 to 0.69), p = 0.002 −0.02 (−0.20 to 0.16), p = 0.80
 24 months 0.48 (0.14 to 0.82), p = 0.006 −0.17 (−0.38 to 0.05), p = 0.13
  1. Analysis of covariance adjusted for age at inclusion in the Epidemiological Investigation of Rheumatoid Arthritis (EIRA), with nulliparous women as reference. ACPA Anti-citrullinated protein antibody, CI confidence interval, DAS28 Disease activity score 28, HAQ health assessment questionnaire, RA Rheumatoid arthritis